---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-025290"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T05:01:02.981956+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AgeX Therapeutics exchanges $36M debt for preferred stock to regain NYSE compliance

## Summary
- Issued 211,600 Series A and 148,400 Series B preferred shares to Juvenescence in exchange for canceling $36M of debt.
- Debt exchange aims to bring AgeX stockholders' equity above $6M; pro forma equity improves from -$20M to ~$16M as of March 31, 2023.
- Each preferred share convertible into common at $0.72/share; conversion subject to 19.9% and 50% caps unless stockholder approval obtained.
- Preferred stock carries no dividends, liquidation preference over common, and limited voting rights.
- Closing expected July 25, 2023, subject to NYSE American approval and filing of certificates of designation.

## SEC filing metadata
- accession: 0001493152-23-025290
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223025290/0001493152-23-025290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223025290/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-025290
- JSON: https://secwatch.observer/filing/0001493152-23-025290.json
- Plain text: https://secwatch.observer/filing/0001493152-23-025290.txt

## Key facts
- Material Agreements
  Serina Therapeutics, Inc. entered into Registration Rights Agreement with Juvenescence Limited (effective 2023-07-21).
  - Action: entry
  - Counterparty: Juvenescence Limited
  - Effective: 2023-07-21
  source text: AgeX and Juvenescence have entered into a Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act of 1933, as amended (the “Securities Act”) the shares of common stock issuable upon conversion of Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223025290/0001493152-23-025290-index.htm
- Material Agreements
  Serina Therapeutics, Inc. entered into Exchange Agreement with Juvenescence Limited valued at $36 Million (effective 2023-07-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Juvenescence Limited
  - Value: $36 Million
  - Effective: 2023-07-21
  source text: On July 21, 2023, AgeX and Juvenescence Limited (“Juvenescence”) entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223025290/0001493152-23-025290-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.